Detalles de la búsqueda
1.
Significant association between high serum CCL5 levels and better disease-free survival of patients with early breast cancer.
Cancer Sci
; 111(1): 209-218, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31724785
2.
Significance of Metabolic Tumor Volume at Baseline and Reduction of Mean Standardized Uptake Value in 18F-FDG-PET/CT Imaging for Predicting Pathological Complete Response in Breast Cancers Treated with Preoperative Chemotherapy.
Ann Surg Oncol
; 26(7): 2175-2183, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-30941655
3.
Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
Breast Cancer Res Treat
; 168(1): 135-145, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29168063
4.
High levels of serum CA15-3 and residual invasive tumor size are associated with poor prognosis for breast cancer patients with non-pathological complete response after neoadjuvant chemotherapy.
J Surg Oncol
; 118(1): 228-237, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29936704
5.
Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
World J Surg Oncol
; 16(1): 26, 2018 Feb 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29433529
6.
[CLINICAL USEFULNESS OF BIOMARKERS FOR BREAST CANCER].
Nihon Geka Gakkai Zasshi
; 117(6): 516-22, 2016 Nov.
Artículo
en Japonés
| MEDLINE | ID: mdl-30173476
7.
An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers.
Breast Cancer
; 30(5): 703-713, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37115435
8.
Relationship between FDG-PET and the immune microenvironment in breast cancer.
Eur J Radiol
; 158: 110661, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36542934
9.
Total Lesion Glycolysis Levels as Predictive Indicators in Patients With Metastatic and Recurrent Breast Cancer Undergoing Endocrine Therapy With or Without CDK4/6 Inhibitor.
Anticancer Res
; 42(10): 4813-4824, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36191999
10.
Absolute Lymphocyte Count Is an Independent Prognostic Factor for ER-positive HER2-negative Advanced Breast Cancer Patients Treated With CDK4/6 Inhibitors.
Anticancer Res
; 42(10): 4867-4878, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36192009
11.
Prognostic Significance of Neutrophil-to-lymphocyte Ratio in Luminal Breast Cancers With Low Levels of Tumour-infiltrating Lymphocytes.
Anticancer Res
; 40(5): 2871-2880, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32366437
12.
Association Between FOXP3/CD8 Lymphocyte Ratios and Tumor Infiltrating Lymphocyte Levels in Different Breast Cancer Subtypes.
Anticancer Res
; 40(4): 2141-2150, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-32234907
13.
C-Reactive Protein and Absolute Lymphocyte Count Can Predict Overall Survival of Patients Treated With Eribulin.
Anticancer Res
; 40(7): 4147-4156, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32620664
14.
Baseline neutrophil-to-lymphocyte ratio and c-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancer.
Oncotarget
; 11(1): 86-98, 2020 Jan 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32002126
15.
High Serum Levels of Interleukin-18 Are Associated With Worse Outcomes in Patients With Breast Cancer.
Anticancer Res
; 39(9): 5009-5018, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31519608
16.
Improved prognosis of low baseline neutrophil-to-lymphocyte ratio is significantly exclusive in breast cancer patients with high absolute counts of lymphocytes.
Mol Clin Oncol
; 10(2): 275-284, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30680208
17.
A Single-centre, Retrospective, Observational Analysis of Fulvestrant for Recurrent/metastatic Breast Cancer According to Metastatic Site.
Anticancer Res
; 39(10): 5653-5662, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31570463
18.
Significance of baseline neutrophil-to-lymphocyte ratio for progression-free survival of patients with HER2-positive breast cancer treated with trastuzumab emtansine.
Sci Rep
; 9(1): 1811, 2019 02 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30755651
19.
Reply to comment on 'An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers' by Fukui et al.
Breast Cancer
; 31(3): 536-538, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38433180
20.
Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers.
Breast Cancer
; 26(6): 738-747, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31098866